文献速递淋巴瘤

纳武利尤单抗联合利妥昔单抗治疗初治滤泡性淋巴瘤:2期1st FLOR研究

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.
PubMed 文献 · Blood Adv · 2025-01-01

这项多中心2期1st FLOR研究纳入39例初治晚期滤泡性淋巴瘤患者,先接受4周期纳武利尤单抗(240 mg)免疫引导,再接受纳武利尤单抗联合利妥昔单抗诱导,随后纳武利尤单抗联合利妥昔单抗维持。诱导期≥3级不良事件发生率为33%,总缓解率92%(完全缓解59%),中位随访51个月,中位无进展生存期61个月,4年无进展生存率58%,4年总生存率95%。

要点

  • 纳武利尤单抗引导后联合利妥昔单抗方案诱导期≥3级不良事件发生率为33%。
  • 总缓解率92%,完全缓解率59%,中位随访51个月时70%的缓解者维持完全缓解。
  • 基线高总代谢肿瘤体积和高总病灶糖酵解与较差无进展生存期相关(P=.04和P=.02)。

核心结论

  • 在初治滤泡性淋巴瘤中,纳武利尤单抗引导后给予纳武利尤单抗联合利妥昔单抗与可接受的毒性和高缓解率相关,可能为化疗提供替代选择。
  • 总代谢肿瘤体积和高肿瘤CD8A表达是有前景的滤泡性淋巴瘤免疫治疗生物标志物。

研究设计与样本

  • 多中心2期1st FLOR研究纳入39例既往未治疗的晚期滤泡性淋巴瘤患者。
  • 治疗方案为4周期纳武利尤单抗(240 mg)引导,随后4周期每2周纳武利尤单抗联合利妥昔单抗375 mg/m2诱导,之后1年每月纳武利尤单抗(480 mg)联合2年每2个月利妥昔单抗维持。
  • 纳武利尤单抗引导后达到完全缓解的参与者继续纳武利尤单抗单药治疗。
  • 主要终点为诱导期间毒性。
  • 试验注册于ClinicalTrials.gov,编号NCT03245021。

主要发现

  • 诱导期间≥3级不良事件发生率为33%(n=13),最常见为淀粉酶/脂肪酶升高(15%)、肝酶异常(11%)和感染(10%)。
  • 3例患者因毒性停止纳武利尤单抗。
  • 总缓解率为92%(完全缓解59%)。
  • 中位随访51个月,中位无进展生存期为61个月(95%CI 2-72),4年无进展生存率为58%(95%CI 34-97);70%的缓解者维持完全缓解。
  • 4年总生存率为95%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) outcomes are influenced by host immune activity. CD20-directed therapy plus programmed cell death 1 inhibition (PD-1i) increases T-cell tumor killing and natural killer cell antibody-dependent cell cytotoxicity. Mounting evidence supports immune priming using PD-1i before cancer directed agents. Our multicenter, phase 2 1st FLOR study enrolled 39 patients with previously untreated advanced-stage FL to receive 4 cycles of nivolumab (240 mg), then 4 cycles of 2-weekly nivolumab plus rituximab 375 mg/m2 (induction), then 1 year of monthly nivolumab (480 mg) plus 2 years of 2-monthly rituximab maintenance. Participants with complete response (CR) after nivolumab priming continued nivolumab monotherapy. The primary end point was toxicity during induction. Adverse events of grade ≥3 during induction occurred in 33% (n = 13); most commonly elevated amylase/lipase (15%), liver enzyme derangement (11%), and infection (10%). Three patients discontinued nivolumab secondary to toxicity. Overall response rate was 92% (CR, 59%). Median follow-up was 51 months. Median and 4-year progression-free survival (PFS) were 61 months (95% confidence interval [CI], 2-72) and 58% (95% CI, 34-97); 70% of responders remained in CR. The 4-year overall survival was 95%. High baseline total metabolic tumor volume (TMTV) and total lesion glycolysis conferred inferior PFS (P = .04 and P = .02). Additionally, high baseline tumor CD8A gene expression was associated with improved PFS (P = .03). Nivolumab priming followed by nivolumab-rituximab in treatment-naïve FL is associated with favorable toxicity and high response rates, potentially providing an alternative to chemotherapy. TMTV and high tumor CD8A expression are promising immunotherapy biomarkers for FL. This trial was registered at www.ClinicalTrials.gov as #NCT03245021.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Barraclough A, Lee ST, Burgess M, et al. Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study. Blood Adv. 2025. PMID: 39853272. doi:10.1182/bloodadvances.2024015487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。